Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?

J Thorac Oncol. 2020 Apr;15(4):489-492. doi: 10.1016/j.jtho.2020.02.003.

¹ Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Program of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
² Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Program of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
³ Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Program of Solid Tumors, Center for Applied Medical Research, University of Navarra, Pamplona, Spain. Electronic address: igbazo@unav.es.

No abstract available

Publication types